eligibility_summary
Adults ≥18 with relapsed/refractory CD20+ NHL. Aggressive LBCL or FL3b: ≥2 prior lines, or ≥1 if ineligible for HDC/auto-HSCT, with anthracycline and anti-CD20 exposure. FL1–3a or MZL: ≥2 prior lines and prior anti-CD20. Measurable disease (Lugano 2014) and ECOG 0–1. Exclude HHV8+ DLBCL, prior allo-HSCT, auto-HSCT <12 wks, uncontrolled infection, recent DVT/PE, major cardiac events, seizures/dementia/optic neuritis, CNS disease, active liver/biliary disease (except Gilbert/gallstones).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JNJ-90009530 (C-CAR066), an autologous anti-CD20 chimeric antigen receptor T-cell (CAR-T) therapy. Mechanism: a patient’s T cells are engineered ex vivo to express a CAR that binds CD20 on B cells, CAR engagement activates the T cells to release cytotoxic molecules and cytokines, eliminating CD20+ malignant B cells (with expected on-target B-cell aplasia). Targets: CD20 antigen on B-cell non-Hodgkin lymphoma cells, pathway: CAR-mediated T-cell activation and effector killing of B-cell tumors. Design: Phase 1b, open-label, single-arm trial in adults with relapsed/refractory B-NHL, objectives are to define a safe, tolerable dose and evaluate response and duration.